Genomma Lab Internacional, S.A.B. de C.V. (GNMLF)
- Previous Close
0.0000 - Open
1.2400 - Bid 1.0400 x 40000
- Ask 1.1600 x 40000
- Day's Range
1.2400 - 1.2400 - 52 Week Range
0.9200 - 1.4300 - Volume
300 - Avg. Volume
29 - Market Cap (intraday)
1.208B - Beta (5Y Monthly) 0.56
- PE Ratio (TTM)
11.27 - EPS (TTM)
0.1100 - Earnings Date Jul 22, 2025 - Jul 28, 2025
- Forward Dividend & Yield 0.04 (3.21%)
- Ex-Dividend Date Mar 13, 2025
- 1y Target Est
--
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and improvement products, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, infant nutrition, and others. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.
www.genommalab.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: GNMLF
View MorePerformance Overview: GNMLF
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P/BMV IPC (^MXX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GNMLF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GNMLF
View MoreValuation Measures
Market Cap
1.07B
Enterprise Value
1.31B
Trailing P/E
11.08
Forward P/E
10.81
PEG Ratio (5yr expected)
0.53
Price/Sales (ttm)
1.26
Price/Book (mrq)
2.13
Enterprise Value/Revenue
1.36
Enterprise Value/EBITDA
5.97
Financial Highlights
Profitability and Income Statement
Profit Margin
12.03%
Return on Assets (ttm)
11.25%
Return on Equity (ttm)
21.11%
Revenue (ttm)
18.82B
Net Income Avi to Common (ttm)
2.2B
Diluted EPS (ttm)
0.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
2.16B
Total Debt/Equity (mrq)
62.63%
Levered Free Cash Flow (ttm)
1.28B